• Prochlorperazine: Dopamine D2 Antagonist for Antiemetic a...

  2026-02-25

  Prochlorperazine, a phenothiazine derivative, is a potent dopamine D2 receptor antagonist used as an antiemetic agent and in melanoma research. It demonstrates inhibition of melanoma cell proliferation and migration at micromolar concentrations and blocks clathrin-mediated endocytosis, underpinning its antiviral activity. APExBIO supplies validated Prochlorperazine (SKU A8508) for advanced cellular and translational workflows.

• Harnessing O-GlcNAcylation: Strategic Applications of Thi...

  2026-02-25

  Thiamet G, a potent and selective O-GlcNAcase inhibitor from APExBIO, is redefining translational research across neurodegeneration, oncology, and bone biology. By enabling precise control of O-GlcNAcylation—a posttranslational modification central to protein function and cellular fate—Thiamet G unlocks new frontiers in disease modeling and therapeutic innovation. This thought-leadership article integrates mechanistic insights, experimental best practices, and forward-looking strategies, informed by the latest literature and landmark studies on O-GlcNAc in bone metabolism, to guide translational researchers in leveraging Thiamet G for next-generation discoveries.

• Tubastatin A (SKU A4101): Reliable HDAC6 Inhibition for C...

  2026-02-24

  This article provides scenario-driven, evidence-based guidance for life science researchers evaluating Tubastatin A (SKU A4101) as a selective HDAC6 inhibitor. Focusing on real-world assay optimization, reproducibility, and product selection, it highlights how Tubastatin A from APExBIO delivers robust, data-backed solutions for cell viability, proliferation, and inflammation workflows.

• Belinostat (PXD101): Pan-HDAC Inhibitor for Epigenetic Ca...

  2026-02-24

  Belinostat (PXD101) is a benchmark hydroxamate-type pan-HDAC inhibitor unlocking powerful, reproducible workflows for cancer researchers targeting histone acetylation modulation. From robust proliferation inhibition in urothelial and prostate models to advanced protocols and troubleshooting, this guide empowers your lab to harness Belinostat’s full potential across diverse in vitro and in vivo applications.

• Tubastatin A: Advancing HDAC6 Inhibition for Cardiac and ...

  2026-02-23

  Explore Tubastatin A, a potent selective HDAC6 inhibitor, and its cutting-edge applications in myocardial injury, cancer biology, and inflammation. This article delves into novel mechanisms and emerging research, offering unique insights beyond standard HDAC6 inhibitor discussions.

• Entinostat (MS-275, SNDX-275): HDAC1/3 Inhibition for Pre...

  2026-02-23

  Entinostat (MS-275, SNDX-275) is a selective, orally available HDAC1 and HDAC3 inhibitor that modulates epigenetic signaling to suppress cancer cell proliferation. Its robust anti-tumor effects are supported by reproducible in vitro and in vivo benchmarks. This article provides atomic, verifiable facts for advanced oncology workflows.

• Panobinostat (LBH589): Advancing Epigenetic Drug Response...

  2026-02-22

  Explore Panobinostat, a potent broad-spectrum HDAC inhibitor, through the lens of state-of-the-art epigenetic drug response profiling. This article uniquely integrates advanced in vitro methodologies with mechanistic insights, offering fresh perspectives for apoptosis induction and resistance studies.

• M344 and the New Frontier in HDAC Inhibition: Mechanistic...

  2026-02-21

  This thought-leadership article unpacks the mechanistic foundations, experimental advances, and translational potential of M344—a potent, cell-permeable histone deacetylase inhibitor (HDACi) with an IC50 of 100 nM. Drawing on recent neuroblastoma findings and the evolving landscape of epigenetic therapy, the piece offers strategic guidance for researchers aiming to harness M344 for cancer and HIV-1 latency research. With a focus on actionable workflows and differentiated insight, this article sets a new benchmark for integrating mechanistic depth with translational impact.

• Tubastatin A: Selective HDAC6 Inhibitor for Translational...

  2026-02-20

  Tubastatin A stands out as a highly selective HDAC6 inhibitor, enabling precise dissection of histone deacetylase signaling in cancer, inflammation, and myocardial protection. Its robust selectivity, documented efficacy, and compatibility with diverse models empower researchers to drive innovation in mechanistic studies and translational therapeutics.

• Medroxyprogesterone Acetate (MPA): Unraveling Novel Pathw...

  2026-02-20

  Explore the multifaceted role of Medroxyprogesterone acetate (MPA) in steroidal progestin research, from progesterone receptor-independent regulation to advanced models of endometrial decidualization and renal epithelial studies. This article delivers a unique, in-depth analysis grounded in the latest molecular findings.

• Tubastatin A and the Future of Precision HDAC6 Inhibition...

  2026-02-19

  This thought-leadership article explores Tubastatin A's role as a highly selective HDAC6 inhibitor, synthesizing mechanistic detail and translational strategy for researchers. We examine the latest experimental evidence—including myocardial protection via cell death modulation—compare the competitive landscape, and chart new horizons for deploying Tubastatin A in advanced disease modeling. By integrating authoritative references and bold perspectives, this piece deepens the discussion beyond standard product pages and positions Tubastatin A as a linchpin for next-generation translational research.

• Prochlorperazine: Mechanistic Insights and Advanced Appli...

  2026-02-19

  Explore how Prochlorperazine, a potent dopamine D2 receptor antagonist, uniquely bridges antiemetic therapy and advanced research into melanoma and antiviral pathways. This article delivers scientific depth, mechanistic clarity, and translational guidance for innovative cancer and virology studies.

• Trichostatin A (TSA): Redefining Epigenetic Research and ...

  2026-02-18

  This thought-leadership article unpacks the mechanistic power of Trichostatin A (TSA)—a benchmark histone deacetylase inhibitor (HDACi)—and provides translational researchers with advanced insights and actionable strategies. From cell cycle arrest to dendritic cell modulation under hypoxia, we bridge mechanistic depth with strategic guidance, address competitive landscapes, and illuminate emerging frontiers in epigenetic therapy and cancer research. Contextual product intelligence for APExBIO's TSA (SKU: A8183) is woven throughout, and the article directly integrates findings from recent breakthrough studies.

• Prochlorperazine: A Dopamine D2 Receptor Antagonist for A...

  2026-02-18

  Prochlorperazine stands out as a versatile phenothiazine derivative that bridges antiemetic therapy and innovative cancer and antiviral research applications. By leveraging its potent dopamine D2 receptor antagonism and inhibition of clathrin-mediated endocytosis, researchers unlock new experimental workflows for melanoma and drug-resistant cancer models.

• NADH (Reduced Nicotinamide Adenine Dinucleotide, CAS No. ...

  2026-02-17

  NADH, a central cellular energy metabolism coenzyme, is essential for mitochondrial electron transport chain research and NADH/NAD⁺ ratio biomarker studies. Rigorous evidence supports its use in metabolic disease modeling and redox signaling pathway analysis. APExBIO’s NADH (SKU: C8749) provides a highly characterized, research-standard reagent for precise experimental workflows.

395 records 7/27 page Previous Next First page 上5页 678910 下5页 Last page